On a quest to double sales, Akorn snags specialized rival VersaPharm in $440M deal | PharmaBoardroom
written on 12.05.2014
Tags:
,

On a quest to double sales, Akorn snags specialized rival VersaPharm in $440M deal

TAGS: ,

Specialty generics maker Akorn has nabbed another niche player. Fresh off the closing of its eye-care-oriented buyout of Hi-Tech Pharmacal, the Lake Forest, IL-based drug company has snapped up VersaPharm for $440 million.

Latest Report